Offering new hope
in the battle against antibiotic
resistant bacteria

Welcome to Auspherix

Auspherix is an anti-infectives company that is developing a novel class of organogold-based antibiotics that are designed to help address the worldwide healthcare crisis of rising antimicrobial resistance (AMR).

Research & Development

Our proprietary organogold chemistry platform is being used to build a pipeline of novel antibacterials with an initial therapeutic focus on complicated urinary tract (cUTI) infections.

read more »

Partnering

Whilst Auspherix is committed to progressing its pipeline of organogold compounds into clinical development, it welcomes strategic partnering opportunities with pharma and biotech companies in the anti-infectives space to expand its R&D capabilities and pipeline.

read more »

Investors

Auspherix is a private biotechnology company that is backed by leading sector investors namely Brandon Capital through the Australian Medical Research Commercialisation Fund (MRCF) and UK-based Touchstone Innovations.

read more »

Auspherix Awarded Innovate UK Grant to Test its Organogold Antibiotics to Treat Life-threatening Respiratory Infections

Auspherix Awarded Innovate UK Grant to Test its Organogold Antibiotics to Treat Life-threatening Respiratory Infections Stevenage, UK – 12 February 2018 – Funding from Innovate UK, the UK’s Innovation agency, is enabling UK anti-infectives company Auspherix to expand into new therapeutic indications and test the activity of its new class of organogold antibacterial compounds against […]

Auspherix Presents Pharmacokinetic-Pharmacodynamic (PK/PD) Profile of its Antibacterial Compounds in Rodents

Auspherix Presents Pharmacokinetic-Pharmacodynamic (PK/PD) Profile of its Antibacterial Compounds in Rodents Data presented at leading antibacterial conference  Stevenage, UK – 19 October 2017 – Auspherix Limited, the anti-infectives company meeting the urgent need for new antibiotics by developing a novel class of antibacterials, today announced that it is presenting proprietary bioanalytical methods to characterise the in […]

December 2016 – PharmaVentures TV

Interview with CEO, Dr Neil Miller, discussing how Auspherix is meeting the urgent need for new antibiotics by developing a new class of organogold antibiotics.

View video on the PharmaVentures TV website

November – MedNous

Interview with CEO, Dr Neil Miller in an article about “The Stately Progress of Antibiotics”.

View PDF

November 2016 – Scrip TV

Interview with CEO, Dr Neil Miller.

Latest Tweets